ClinicalTrials.gg
RecruitingNCT04622462Updated Nov 7, 2024

Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

An observational study in Oral Neoplasm, sponsored by Proteocyte Diagnostics Inc.. Recruiting at 3 sites in Canada. Open to participants aged 15 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Proteocyte Diagnostics Inc. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2015; still recruiting 11 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
15 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Mouth Neoplasms with a site in Canada — 7 open to participants now, 9 under way, 1 of them phase 3. Mouth Neoplasms · Canada.

Started
2015
the only one that year
Observational
3 of 23
1 open now
Registered
17th of 23
by date

Among the 23 studies in Mouth Neoplasms with a site in Canada, this one is the only one that started in 2015, is one of 3 observational ones, and was the 17th registered.

Mouth Neoplasms

447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.

Browse Mouth Neoplasms studies →

Open to participants now

7 of the 23 studies in Mouth Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 97 Mouth Neoplasms studies recruiting now, 58 (60%) set no upper age limit and 23 (24%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 15 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Mouth Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.

Read the detailed description

Background: The standard of care for potentially premalignant oral epithelial lesion (PPOEL) risk assessment for progression to cancer is dysplasia grading by histopathology. With significant overlap between dysplasia grades and high inter- and intra-observer variations, dysplasia grading alone has been shown to be inadequate as a prognostic tool. To investigate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in the early diagnosis of invasive oral cancer, a prospective multi-center observational study was designed with specimens obtained from community-based practices.

Methods: Patients that qualify to enroll in the study will be assessed for both standard of care histopathological assessment for dysplasia grade and STRATICYTE risk assessment, and followed for up to 60 months (from initial biopsy) to determine the outcome of their oral lesion(s).

03

Conditions studied

  • Oral Neoplasm

Keywords

  • Leukoplakia
  • Erythroplakia
  • Erythroleukoplakia
  • Lesion
  • Oral Epithelial Dysplasia
  • S100A7 Biomarker
  • S100A7 Immunohistochemistry Signature-based
  • Early Diagnosis
  • STRATICYTE
  • Oral Neoplasia
  • Oral Epithelial Atypia
  • Hyperplasia
  • Hyperkeratosis
  • Oral Squamous Cell Carcinoma
  • Oral Cancer
  • Potentially Premalignant Oral Epithelial Lesion
  • OPMD
  • Mild Dysplasia
  • Moderate Dysplasia
  • Severe Dysplasia
  • Low-grade Dysplasia
  • High-grade Dysplasia
  • Personalized Medicine
  • Predictive Assay
  • Whole Slide Imaging
  • Computational Pathology
  • Digital Pathology
  • Artificial Intelligence
  • Machine Learning
  • OPML
  • Oral Potentially Malignant Disorder
  • Oral Potentially Malignant Lesion
04

Who can participate

Ages eligible
15 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will be selected from community-based Oral \& Maxillofacial Surgery practices in the provinces of Ontario and Alberta, Canada

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma

Exclusion criteria

Exclusion Criteria:

  • Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Oral Mucosal Biopsies With or Without Evidence of Epithelial Dysplasia

    No evidence of dysplasia Mild dysplasia Moderate dysplasia Severe dysplasia

    Procedure: Standard of Care Histopathology · Procedure: STRATICYTE Assessment

Interventions

  • ProcedureStandard of Care Histopathology

    Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer

    Also known as: H&E assessment for dysplasia grade

  • ProcedureSTRATICYTE Assessment

    Assessment for risk of progression to oral cancer

    Also known as: S100A7 Immunohistochemistry Signature-based Assessment

06

What researchers measure

Primary outcomes

  1. Malignant Transformation Rate: Dysplasia

    Cancer progression rate in patients with oral neoplasia with dysplasia and STRATICYTE Low-Risk or Elevated Risk

    Time frame: 60 months

Secondary outcomes

  1. Malignant Transformation Rate: No Dysplasia

    Cancer progression rate in patients with oral neoplasia without dysplasia and STRATICYTE Low-Risk or Elevated-Risk

    Time frame: 60 months

  2. Recurrence Rate

    Recurrence rate in patients with oral neoplasia with or without dysplasia and STRATICYTE Low-Risk or Elevated-Risk

    Time frame: 60 months

07

Study locations

3 of 3 sites recruiting
  • Kingsway Oral & Maxillofacial Surgery
    Edmonton, Alberta T5M 3Z7, Canada
    Recruiting
    • Tim McGaw, DDS, MSc, MD · Contact
  • University of Alberta
    Edmonton, Alberta T6G 1C9, Canada
    Recruiting
    • Tim McGaw, DDS, MSc, MD · Contact
  • Western University
    London, Ontario N6A 5C1, Canada
    Recruiting
    • Mark Darling, MSc, MChD · Contact
08

References and documents

Publications

  • Hwang, J.T.K., Dammling, C., McCord, C. et al. External Validation of Straticyte™, a Quantitative Biomarker-Based Risk Assay in Predicting Oral Cancer. J. Maxillofac. Oral Surg. (2024). https://doi.org/10.1007/s12663-024-02362-7
  • Hwang JT, Gu YR, Shen M, Ralhan R, Walfish PG, Pritzker KP, Mock D. Individualized five-year risk assessment for oral premalignant lesion progression to cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Mar;123(3):374-381. doi: 10.1016/j.oooo.2016.11.004. Epub 2016 Nov 22. PubMed 28110942 ↗
  • Kaur J, Matta A, Kak I, Srivastava G, Assi J, Leong I, Witterick I, Colgan TJ, Macmillan C, Siu KW, Walfish PG, Ralhan R. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia. Int J Cancer. 2014 Mar 15;134(6):1379-88. doi: 10.1002/ijc.28473. Epub 2013 Oct 8. PubMed 24122701 ↗
  • Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R, Siu KW. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS One. 2010 Aug 3;5(8):e11939. doi: 10.1371/journal.pone.0011939. PubMed 20689826 ↗
  • Ralhan R, Desouza LV, Matta A, Tripathi SC, Ghanny S, Dattagupta S, Thakar A, Chauhan SS, Siu KW. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res. 2009 Jan;8(1):300-9. doi: 10.1021/pr800501j. PubMed 19072117 ↗
  • Ralhan R, Desouza LV, Matta A, Tripathi SC, Ghanny S, Datta Gupta S, Bahadur S, Siu KW. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics. 2008 Jun;7(6):1162-73. doi: 10.1074/mcp.M700500-MCP200. Epub 2008 Mar 13. PubMed 18339795 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2015 (actual). Primary completion is estimated for Dec 2025, 129 months after the start.

Of 48 observational studies under Mouth Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 216. This study's planned 129 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2020
First posted
Nov 10, 2020
StartActual
Mar 12, 2015
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04622462
Lead sponsor
Proteocyte Diagnostics Inc.
Responsible party
Sponsor
First posted
Nov 10, 2020
Start date
Mar 12, 2015
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 7, 2024

Study contacts

Jason Hwang, PhD
Contact
jhwang@proteocyte.com
(647) 255-1370
Mark Darling, MSc, MChD
Contact
mark.darling@schulich.uwo.ca
(519) 661-2111 ext. 86399
Mark Darling, MSc, MChD
principal investigator · Western University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion